Passage Bio
Focus: Passage Bio is a Philadelphia-based gene therapy biotech focused on treating CNS and genetic disorders, including frontotemporal dementia and lysosomal storage diseases. The company operates at pre-revenue stage with a focused pipeline and early-stage development programs.
Profile data last refreshed 19h ago · AI intelligence enriched 1w ago
Open Jobs
14
Should You Work at Passage Bio?
AI assessmentPassage Bio offers high scientific impact and frontier gene therapy exposure, but financial opacity and early-stage status create material career and stability risk.
Why Work Here
- Gene therapy is a high-growth scientific frontier with limited competition; working here positions you at the cutting edge of CNS and genetic disease treatment
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Confirmatory Testing
Acid Sphingomyelinase DeficiencyNatural History Study of Infantile and Juvenile GM1 Gangliosidosis (GM1) Patients
GM1 GangliosidosisHelp build intelligence for Passage Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.